Company
Headquarters: Camberwell, VIC, Australia
CEO: Mr. Jonathan Charles Pilcher A.C.A., B.Sc., BSc (Hons), ACA
A$2.60 Billion
AUD as of July 1, 2024
US$1.73 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | A$231.9 M |
| EBITDA | A$199.2 M |
| Gross Profit TTM | A$231.9 M |
| Profit Margin | 67.72% |
| Operating Margin | 89.40% |
| Quarterly Revenue Growth | 996.30% |
Neuren Pharmaceuticals Limited has the following listings and related stock indices.
Stock: ASX: NEU wb_incandescent